Latest Financial Results

Q2 2020

Quarterly Results

Ended Apr 30, 2020

Stock Information

Symbol

ANIX

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.  Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function.  The company’s vaccine portfolio consists of a technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC).  Anixa continually examines emerging technologies in complementary fields for further development and commercialization.

Logo Itus

Latest News & Events

Anixa Biosciences' CAR-T Cancer Therapy Receives Intention to Grant Notice from the European Patent Office

Read More...

Anixa and OntoChem Announce Completion of Initial Screening Program and Identification of Additional Covid-19 Compounds

Read More...

Anixa Announces Strategic Program Realignment Focused on Advancement of its Therapeutic and Vaccine Pipeline

Read More...